https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offers-800m-kelonias-vivo-delivery-know-how
Astellas buying up, pre-clinic.
Astellas bought Xyphos back in 2019 for $120 million upfront with more than $500 million in biobucks available.
Xyphos linking arms with Kelonia in a research and licensing deal worth north of $800 million. Kelonia will receive a $40 million upfront payment for its work and could snag another $35 million should Xyphos buy into the second. The total amount of milestone and contingency payments is close to $800 million.
https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offer...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |